Clinical trials

Amorphical’s Clinical Trials

Explore Amorphical’s clinical trials highlighting the power of Israeli innovation and our patented amorphous minerals—backed by science and proven to support bone health, recovery, and inflammation.

  1. A randomized, double-blind, crossover bioavailability study comparing synthetic ACC versus CCC using stable calcium isotopes in early postmenopausal women. NCT01338142
  2. A randomized, double-blind, crossover bioavailability study comparing synthetic ACC versus CCC using stable calcium isotopes in early postmenopausal women. NCT01338142
  3. A randomized, two-phase, adaptive, then crossover open-label study comparing amorphous calcium carbonate (ACC) supplement versus commercially available crystalline calcium
    supplements (CCS) in the management of primary hypoparathyroidism. NCT01815021
  4. Safety, Tolerability and Efficacy of Amorphous Calcium Carbonate (ACC) Compared to Placebo and Best Available Care (BAT), for the Treatment of Moderate to Severe COVID-19 Patients. NCT04900337
  5. A prospective, randomized, parallel, double-blind, placebo-controlled pilot study comparing the effect of Amorphous Calcium Carbonate (ACC) versus placebo on functional outcome and radiographic healing time of distal radius fractures. NCT01859468
  6. An exploratory, open label study to improve the function and welfare of late-stage solid cancer subjects (with or without lung involvement) by Amorphous Calcium Carbonate (ACC) treatment, administered orally and concomitantly with inhalation. NCT03057314
  7. Randomized, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Amorphous Calcium Carbonate (ACC) in Rheumatoid Arthritis Patients with Osteopenia or Osteoporosis, Compared to Crystalized Calcium Carbonate (CCC). NCT05443360
  8. Randomized, Parallel, Placebo-controlled study, to assess the safety, tolerability, and efficacy of PH Gastrilex in the treatment of adult subjects with moderate to severe Crohn’s Disease (Israeli Ministry of health study number: MOH_2023-05-01_012591).
  9. A Phase 2, Prospective, Multinational, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of AMOR-1 as a Treatment of Hypocalcemia Associated with Hypoparathyroidism by Replacement of Currently Used Calcium Supplements (CS) in Adults with Hypoparathyroidism. The study received FDA IND clearance and is planned to be initiated in Q2 NCT06547151

 

Skip to content